|Other Names||Disintegrin and metalloproteinase domain-containing protein 11, ADAM 11, Metalloproteinase-like, disintegrin-like, and cysteine-rich protein, MDC, ADAM11, MDC|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP14066a was selected from the N-term region of ADAM11. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Probable ligand for integrin in the brain. This is a non catalytic metalloprotease-like protein.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed predominantly in brain. Slightly detected or not at all in other tissues|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the ADAM (a disintegrin andmetalloprotease) protein family. Members of this family aremembrane-anchored proteins structurally related to snake venomdisintegrins, and have been implicated in a variety of biologicalprocesses involving cell-cell and cell-matrix interactions,including fertilization, muscle development, and neurogenesis. Thisgene represents a candidate tumor supressor gene for human breastcancer based on its location within a minimal region of chromosome17q21 previously defined by tumor deletion mapping. [provided byRefSeq].
Fu, G.K., et al. Genomics 84(1):205-210(2004)Hillman, R.T., et al. Genome Biol. 5 (2), R8 (2004) :Shea, S.H., et al. Behav. Genet. 31(2):231-239(2001)Sagane, K., et al. Biochem. J. 334 (PT 1), 93-98 (1998) :Wolfsberg, T.G., et al. J. Cell Biol. 131(2):275-278(1995)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.